We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Our antivirals target the replication process and are designed to be safe, broad-spectrum, resistant and convenient to administer.

We are quickly and efficiently advancing multiple programs with clinical development underway for influenza, norovirus and coronaviruses, while also discovering and developing antiviral compounds for other high-value indications.

Nasdaq Bell Ringing Ceremony